See today's BioWorld
To read the full story, subscribe or sign in.

Arovella heads toward clinic with CAR-19-iNKT cells

Nov. 27, 2024
By Tamra Sami
Arovella Therapeutics Ltd. is heading toward the clinic with its lead product, ALA-101, which consists of a chimeric antigen receptor (CAR) targeting CD19 and invariant natural killer T (iNKT) cells.
BioWorld Clinical Regulatory Cancer CAR T Cell therapy Asia-Pacific Australia U.S.